Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer

BACKGROUND: Triple negative breast cancer (TNBC) is an incurable disease where novel therapeutic strategies are needed. Proteolysis targeting chimeric (PROTAC) are novel compounds that promote protein degradation by binding to an ubiquitin ligase. In this work, we explored the antitumoral activity o...

詳細記述

保存先:
書誌詳細
出版年:J Exp Clin Cancer Res
主要な著者: Noblejas-López, María del Mar, Nieto-Jimenez, Cristina, Burgos, Miguel, Gómez-Juárez, Mónica, Montero, Juan Carlos, Esparís-Ogando, Azucena, Pandiella, Atanasio, Galán-Moya, Eva M., Ocaña, Alberto
フォーマット: Artigo
言語:Inglês
出版事項: BioMed Central 2019
主題:
Research
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6717344/
https://ncbi.nlm.nih.gov/pubmed/31470872
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-019-1387-5
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料